The QualityStocks Daily Wednesday, April 30th, 2025

Today's Top 3 Investment Newsletters

Schaeffer's(RGLS) $7.9800 +136.80%

CurrencyNewsWire(RIOT) $7.9800 +136.80%

Premium Stock Alerts(NVNI) $0.4499 +111.22%

The QualityStocks Daily Stock List

Regulus Therapeutics (RGLS)

QualityStocks, StreetInsider, The Street, MarketBeat, Marketbeat.com, AllPennyStocks, BUYINS.NET, StockMarketWatch, Barchart, InvestorPlace, Investing Futures, Kiplinger Today, Jason Bond, Investment House, Goldman Small Cap Research, FreeRealTime, Dividend Opportunities, 360 Wall Street, INO.com Market Report, 247 Market News, Money Morning, Zacks, Profit Confidential, RedChip, Schaeffer's, Street Insider, Streetwise Reports, The Motley Fool, The Online Investor, TradersPro, Trades Of The Day, Wealth Daily, Weekly Wizards and MarketClub Analysis reported earlier on Regulus Therapeutics (RGLS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Regulus Therapeutics Inc. (NASDAQ: RGLS) (FRA: 7RG1) is a biopharmaceutical firm which is focused on the discovery and development of drugs that treat and prevent metabolic, immune-inflammatory, oncology and cardiovascular diseases as well as fibrosis and hepatitis C infections.

Regulus Therapeutics has its headquarters in San Diego, California and was established on Sep-tember 5, 2007. The firm is a part of the biotechnology research services industry and serves con-sumers across the globe.

Regulus Therapeutics has collaborated with AstraZeneca to cure prediabetes/type 2 diabetes and with Sanofi to develop a compound that targets orphan ailments.

Regulus Therapeutics’ product portfolio includes RGLS4326 and RG-012. The former has been developed to target miR-17 and is currently undergoing a phase 1 clinical trial for the treatment of autosomal dominant polycystic kidney disease while the latter, which targets miR-21 is undergoing a phase 2 clinical trial to test for its effectiveness in treating life-threatening kidney diseases known as Alport syndrome. The firm has also developed RG-125, which targets microRNA-103/107 and RG-101 which targets miR-122. Regulus Therapeutics is also developing various preclinical drug product candidates in central nervous systems, hepatic and renal ailments.

Regulus Therapeutics (RGLS), closed Wednesday's trading session at $7.98, up 136.7953%, on 28,566,734 volume. The average volume for the last 3 months is 22,610 and the stock's 52-week low/high is $0.8301/$8.2.

Abeona Therapeutics (ABEO)

MarketBeat, MarketClub Analysis, TraderPower, StockMarketWatch, InvestorPlace, Streetwise Reports, StreetInsider, PCG Advisory, BUYINS.NET, Kiplinger Today, Money Morning, Barchart, SmallCap Network, QualityStocks, Marketbeat.com, StockEarnings, Investopedia, Wall Street Mover, Daily Trade Alert, Equities.com, Trades Of The Day, Short Term Wealth, TopPennyStockMovers, Zacks, Street Insider, Money Map Press, StockOodles, Stock News Now, Stock Beast and Traders For Cash Flow reported earlier on Abeona Therapeutics (ABEO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Abeona Therapeutics Inc. (NASDAQ: ABEO) (FRA: PCJP) is a clinical-stage biopharmaceutical firm that is focused on the development of cell and gene therapies for fatal rare genetic illnesses.

The firm has its headquarters in New York and was incorporated in 1974. Prior to its name change in June 2015, the firm was known as PlasmaTech Biopharmaceuticals Inc. It operates as part of the pharmaceutical manufacturing industry, under the health care sector, in the biotech and pharma sub-industry.

The company utilizes its multi-platform expertise in the manufacture, delivery, development and discovery of new cell and gene therapies. Its fully operational manufacturing facility produces vec-tors and therapies for clinical and pre-clinical studies.

The enterprise’s pipeline is made up of a formulation dubbed ABO-5OX, which has been devel-oped to treat genetic eye disorders; a formulation known as ABO-401, which is indicated for the treatment of cystic fibrosis and ABO-201, which has been developed to treat CLN3 disease. It also develops an AAV-based gene therapy dubbed ABO-101, indicated for the treatment of the Sanfil-ippo syndrome type B; an adeno-associated gene therapy which is virus-based known as ABO-102, which was developed to treat the Sanfilippo syndrome type A; and a gene-corrected autolo-gous cell therapy dubbed EB-101, developed for recessive dystrophic epidermolysis bullosa.

Abeona Therapeutics (ABEO), closed Wednesday's trading session at $6.56, up 23.7736%, on 18,507,617 volume. The average volume for the last 3 months is 9,787,516 and the stock's 52-week low/high is $3.75/$7.3236.

American Diversified Holdings (ADHC)

Mina Mar Marketing Group, OTCReporter, MarketClub Analysis, OTCPicks, OTC Advisors, BullRally, Willy Wizard, CoolPennyStocks, PennyStocks24, HotOTC, Stockpalooza, StockEgg, QualityStocks, Stock Rich, Penny Invest, Stock Stars, Penny stock Profitz, OTCPennyPicks.com, MadPennyStocks, PennyInvest, PennyStockDD, OTCNewsAlerts.com, PennyStockVille, PennyTrader Publisher, MicrocapAlliance, Stock Brain, HotOTCPicks.com, Real Pennies, HotOTCChina.com, HotOTCBuzz.com, The Penny Stock Bull, SmartPennyInvest.com, HotPennyInvest.com, Promotion Stock Secrets, StockRich, Stock Traders Chat, Stockhunter.us, MicrocapVoice, Epic Stock Picks, Fast Money Alerts, Fortune Stock Alerts, Marketbeat.com, JumpingPennyStocks.com, Investinginstockmarket.net, Penny Stocks Pushers, GusherStocks, PSNO.ORG, Wise Micro Cap Consulting, Wall Street Stallions, The Stock Wrangler, StockRockandRoll, Stock Shock and Awe, Stock Exploder, SpeculatingStocks, Penny Stock Rumble, RockingStocks.com, MyBestStockAlerts, POSstocks, PennyPickAlerts, WiseAlerts, Penny Stock Whispers, Bird Gang Stocks, Penny Stock Mobsters, Penny Stock General, Orbit Stocks and SmallCapStockPlays reported earlier on American Diversified Holdings (ADHC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

American Diversified Holdings Corp. (OTC: ADHC) is a holding firm which is focused on providing management services to micro-capital companies in the public and private sectors.

The firm has its headquarters in Del Mar, California and was founded in 20001, on March 21. Be-fore changing its name in October 2007, the firm was known as Cost Containment Technologies Inc. It mainly serves micro-cap public firms.

The company offers financial advisory, administrative support, corporate governance and executive management services as well as introduction to capital sources to micro-cap private and public firms that have proven business models and revenues. Its other services include filing, secretarial and accounting support. However, the firm is yet to generate any revenues.

In addition, the company is developing a platform for use by the Mobile Health Care Market. This division will concentrate on mobile healthcare applications that have been tailored for different pro-tocols and treatments. This will allow healthcare practitioners to be able to constantly alter treat-ments, obtain instant feedback and monitor their patients. The enterprise’s current business Brazos Biomedical Inc., is currently working on a patented non-opioid bio-device product indicated for the treatment of serious migraines.

American Diversified Holdings (ADHC), closed Wednesday's trading session at $0.00135, up 22.7273%, on 84,745,756 volume. The average volume for the last 3 months is 6,556,795 and the stock's 52-week low/high is $0.0006/$0.0049.

GR Silver Mining Ltd. (GRSLF)

QualityStocks and Top Pros' Top Picks reported earlier on GR Silver Mining Ltd. (GRSLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GR Silver Mining Ltd. is a Mexico-focused company. It concentrates on the discovery of gold-silver de-posits in the prolific Rosario Mining District, Sinaloa, Mexico. The Company’s flagship project is the ad-vanced San Marcial Project, where GR Silver Mining recently released its maiden NI 43-101 resource of 36 Moz AgEq (Indicated) and 11 Moz AgEq (Inferred).

Founded in 2012, GR Silver Mining is based in Vancouver, British Columbia. The Company previously went by the name Goldplay Exploration Ltd. It changed its corporate name to GR Silver Mining Ltd. in January of this year.

The Company’s exploration team has more than 10 years of experience in the Rosario District with a rec-ord of successful discoveries. This includes the extension of Mako Mining Corp.’s “La Trinidad” mine, one of Mexico’s highest grade, open pit goldmines. GR Silver Mining’s 250-plus sq. km. exploration portfolio encompasses some of the most prospective areas in the Rosario District.

GR Silver Mining is positioned to control important assets in the Rosario Mining District. It has cost-effective discovery success at San Marcial (May 2018 to Feb 2019); a 60 percent increase in NI 43-101 resource - 40 Moz Ag (47 Moz AgEq). Furthermore, the Company has a more than 400 drill hole data-base (recent and historical). Mine infrastructure and key permits are in place.

Additionally, GR Silver Mining has its Plomosas Silver Project. The Plomosas Project includes five shallow past producing underground mines. These are the Plomosas-La Cruz mine, the San Juan mine, the La Colorada mine, the El Huarache mine, and the El Saltito mine.

GR Silver Mining Ltd. (GRSLF), closed Wednesday's trading session at $0.095, up 22.0295%, on 1,129,163 volume. The average volume for the last 3 months is 659,125 and the stock's 52-week low/high is $0.07/$0.2135.

MKDWELL Tech (MKDW)

Premium Stock Alerts and QualityStocks reported earlier on MKDWELL Tech (MKDW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MKDWELL T

The firm has its headquarters in Hsinchu, Taiwan and was incorporated in 2023, on July 25th. It primarily serves consumers in Mainland China and Taiwan.

MKDWELL Tech operates primarily through its subsidiaries, such as MKDWELL (Jiaxing) Elec-tronics Technology Company Limited. It manufactures and supplies automotive electronics for passenger cars, modified commercial vehicles, camper vans and logistics vehicles. Its business coverage extends from research and development, design, and production to sales of automotive electronic products. The company designs, manufactures and supplies its products to customers through its design center located in Hsinchu Science Park, Taiwan; and its manufacturing plant in Jiaxing Science and Technology City, Jiaxing City, Zhejiang Province, China.

The enterprise’s main products include the Telematics Box (T-BOX), which provides a system for exchanging voice and other information between vehicles and network services in the back-ground; the Wireless Charging Module (WCM), designed to use electromagnetic induction to transfer energy to mobile devices; a modified car program to help improve passenger comfort and convenience; and a seat control module which can control different motor operations, heating, ventilation and other functions of a smart setup to better meet the comfort of driver and passen-gers. In addition, it offers intelligent camper vans control systems and intelligent container con-trol systems for logistics vehicles.

The firm, which recently announced its latest financial results, remains committed to improving product quality to help grow consumer dependence and trust in the firm while also extending its consumer reach. This may in turn help generate additional value for the firm’s shareholders.

MKDWELL Tech (MKDW), closed Wednesday's trading session at $0.28, off by 4.4369%, on 897,006 volume. The average volume for the last 3 months is 95,860 and the stock's 52-week low/high is $0.17/$16.

Trulieve Cannabis Corp. (TCNNF)

QualityStocks, InvestorPlace, CannabisNewsWire, MarketBeat, Wealth Insider Alert, Daily Trade Alert, Cabot Wealth, Top Pros' Top Picks, The Street, Trades Of The Day, Profit Trends, TradersPro, The Online Investor, StreetInsider and Prism MarketView reported earlier on Trulieve Cannabis Corp. (TCNNF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Marijuana businesses operating legally across different states face a complicated reality when it comes to product testing. Without federal regulations, states have built their own rules around lab licensing, testing requirements, sampling methods, and even how to handle contaminated products.

This patchwork approach creates major headaches for companies, especially those working in multiple states, leading to inconsistent results, unexpected recalls, and financial risks.

In every legal state, cannabis must pass quality testing before reaching consumers. Labs need to be approved at the state level, but the way states license and accredit labs varies widely. Many states require labs to meet ISO standards for accuracy and reliability, while others have created alternative accreditation systems.

Since no nationwide testing methods exist, labs often develop their own procedures to meet local regulations, making it difficult to compare results across different regions.

One major problem is the inconsistency in what marijuana products must be tested for. Microbial contamination is a good example—some states demand zero tolerance for specific bacteria or mold, while others allow small amounts.

Pesticide testing rules also differ. Some states enforce strict bans on any pesticide residue, while others set thresholds, meaning trace amounts might still pass. Heavy metal testing is another area with differences. While most states test for mercury, arsenic, lead, and cadmium, some also require screening for additional metals like nickel and chromium.

THC potency testing is one of the few areas with broad agreement: almost all states require labs to measure THC levels for labeling. Still, states differ on how they calculate and define “Total THC” and whether they require testing for other cannabinoids like CBG or CBN.

Testing also changes depending on the product type. Marijuana flower usually faces the broadest testing requirements, while concentrates and edibles may have modified standards. For instance, concentrates often undergo solvent testing to ensure no harmful extraction chemicals are left behind. However, microbial testing may be relaxed for certain concentrate products since the extraction process can eliminate some microbes.

When it comes to topicals, edibles, and beverages, testing standards diverge even more. Some states believe that if the extract used in an edible passed all testing, the finished product doesn’t need to be retested. Others insist that the final product must be checked again.

Sampling procedures add another layer of inconsistency. Some states allow licensees to collect their own samples, while others require labs or neutral parties to do it to prevent tampering. Sampling sizes also vary: some states base it on a percentage of the batch, others on weight guidelines. These differences affect the reliability of test results and encourage practices like “lab shopping,” where companies look for labs that might deliver more favorable outcomes.

When a batch fails testing, the consequences depend heavily on local rules. Some states require immediate destruction, especially for serious contamination such as banned pesticides. Others allow remediation efforts, giving businesses a chance to fix and retest their products.

For marijuana operators trying to stay compliant, this fragmented system isn’t just a paperwork hassle—it can cause real financial damage. A failed batch, product recall, or lawsuit over testing can cost companies millions. Even when businesses do everything by the book, they might get caught up in recalls caused by lab errors or inconsistent standards.

For instance, Michigan regulators recalled all marijuana products tested over three months by a major laboratory in 2021. More than 400 dispensaries were impacted, and about $229 million worth of products were pulled from shelves.

As the industry evolves, businesses, regulators, and labs need a more unified system with shared testing standards and methods. Standardization would protect consumers, provide more stability for companies, and create a safer, more trustworthy industry overall.

For companies like Trulieve Cannabis Corp. (CBoe CA: TRUL) (OTCQX: TCNNF) that focus on making and selling medical marijuana products, uniform cannabis testing rules and practices are very important since lives can be impacted adversely if this crucial testing phase isn’t uniformly undertaken.

Trulieve Cannabis Corp. (TCNNF), closed Wednesday's trading session at $4.94, up 6.2366%, on 1,081,525 volume. The average volume for the last 3 months is 12,351,720 and the stock's 52-week low/high is $3.02/$14.425.

Monogram Technologies (MGRM)

Greenbackers, OTCPicks, MarketBeat, Market Alerts and 360 Wall Street reported earlier on Monogram Technologies (MGRM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Monogram Technologies (NASDAQ: MGRM) , an AI-driven robotics company transforming orthopedic surgery, has received approval from India’s Central Drugs Standard Control Organization to import its mBôs TKA system and begin a 102-patient, multi-center clinical trial in partnership with Shalby Limited (NSE: SHALBY). The study will evaluate the safety and effectiveness of Monogram’s robotic total knee replacement system using a Consensus CKS implant and include three-month clinical follow-up across multiple Indian sites. Monogram will deploy full-time staff to support training and execution, with surgeries expected to begin within 90 business days. CEO Benjamin Sexson called the approval a major milestone toward commercial launch, while partners from Reliance Life Sciences and Shalby praised the trial’s potential to elevate global orthopedic standards.

To view the full press release, visit https://ibn.fm/RX3Iy

About Monogram Technologies Inc.

Monogram Technologies (NASDAQ: MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics.

Monograms mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The goal is well balanced, better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mBôs with mVision navigation are also being explored.

Monogram has obtained FDA clearance for mPress implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market its products. Monogram cannot estimate the timing or assure the ability to obtain such clearances.

The Company believes that its mBôs precision robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee implants for patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates that there may be other clinical and commercial applications for its navigated mBôs precision robot and mVision navigation.

For more information, please visit www.monogramtechnologies.com .

Monogram Technologies (MGRM), closed Wednesday's trading session at $3.05, up 5.9028%, on 30,190 volume. The average volume for the last 3 months is 212,143,639 and the stock's 52-week low/high is $1.82/$4.205.

Eloro Resources (ELRRF)

QualityStocks, Tip.us, MissionIR, SeriousTraders, MiningNewsWire, InvestorBrandNetwork, SmallCapRelations, Tiny Gems, Stocks to Buy Now, StocksToBuyNow, SmallCapSociety, Rocks & Stocks, NetworkNewsWire, TradersPro and rocksandstocks reported earlier on Eloro Resources (ELRRF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM) , advancing its Iska Iska silver-tin polymetallic project in southwestern Bolivia, will soon begin a 4,300-meter, eight-hole diamond drilling program targeting the Santa Barbara starter pit area. The campaign is designed to upgrade and expand high-grade tin and silver mineralization, with holes spaced at 50 meters to confirm continuity. CEO Tom Larsen said prior drilling extended mineralization and revealed new targets, contributing to a significantly expanded footprint. The upcoming 2025 phase 1 campaign will further assess the zone’s resource potential to support an updated PEA, with ongoing metallurgical studies showing promising results.

To view the full press release, visit https://ibn.fm/WH8dk

About Eloro Resources Ltd.

Eloro is an exploration and mine-development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec. Eloro has an option to acquire a 100% interest in the highly prospective Iska Iska Property, which can be classified as a polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department in southern Bolivia. A recent NI 43-101 technical report on Iska Iska, which was completed by Micon International Limited, is available on Eloro’s website and under its filings on SEDAR. Iska Iska is a road-accessible, royalty-free property. Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the north-central mineral belt of Peru, some 50 kilometers south of the Lagunas Norte Gold Mine and the La Arena Gold Mine. For more information about the company, visit www.EloroResources.com .

Eloro Resources (ELRRF), closed Wednesday's trading session at $0.7059, up 0.742115%, on 107,350 volume. The average volume for the last 3 months is 10,491,448 and the stock's 52-week low/high is $0.54/$1.39.

Fifty 1 Labs (FITY)

QualityStocks and BioMedWire reported earlier on Fifty 1 Labs (FITY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Fifty 1 Labs (OTC: FITY) , a leader in technology and wellness innovation, has appointed Michael Lawson as CEO and Chairman while launching its new BioSentry Division focused on advanced biohazard detection. The division will develop real-time sensor systems using PCR, spectrometry and AI-driven analytics to detect biological, chemical and environmental threats, with applications spanning defense, public health, and industrial safety. The company also announced a strategic partnership with UAV Corp (OTC: UMAV) to integrate the sensors with UAVs and plans to issue a UMAV share dividend to FITY shareholders. Meanwhile, Fifty 1 Labs has opted not to proceed with the Genetic Networks acquisition and remains focused on securing Department of Defense contracts. Brandon Spikes and Robert Clark will continue in key leadership roles as the company advances its dual focus on safety and wellness technologies.

To view the full press release, visit https://ibn.fm/EMAyM

About Fifty 1 Labs, Inc.

Fifty 1 Labs, Inc. (OTC: FITY), a Nevada corporation based at 751 North Drive, Melbourne, FL 32934, is a holding company driving innovation in health, wellness, and biotechnology. FITY owns 100% of Genetic Networks LLC, a Delaware-based biotech firm founded in 2015 by Dr. Gennaro D’Urso. Genetic Networks, headquartered in Miami, Florida, develops the GeneScape ™ platform, a yeast-based, whole-genome analysis tool that accelerates drug discovery for personalized medicine, biodefense, and wellness applications, with proven success serving major pharma clients like Bristol Myers Squibb. FITY also wholly owns 51, LLC, its sports nutrition subsidiary offering a premium line of supplements—including pre-workout formulas, BCAAs, ION+ Electrolyte Formula, Turmeric Gummies, and Ashwagandha Gummies—designed to enhance athletic performance, recovery, and overall health. The Quickness, Astound NMN, and Drago Knives have been merged out of the company and are no longer part of Fifty 1 Labs, Inc., sharpening FITY’s focus on biotech and wellness synergies to empower individuals and organizations worldwide.

For more information, visit the company’s website at https://fifty1labs.com/

Fifty 1 Labs (FITY), closed Wednesday's trading session at $0.0051, up 2%, on 14,990,902 volume. The average volume for the last 3 months is 175,562 and the stock's 52-week low/high is $0.0004/$0.043.

Sekur Private Data (SWISF)

QualityStocks, SmallCapRelations, SeriousTraders, MissionIR, InvestorBrandNetwork, Tiny Gems, Stocks to Buy Now, Tip.us, StocksToBuyNow, TechMediaWire, SmallCapSociety and NetworkNewsWire reported earlier on Sekur Private Data (SWISF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FSE: GDT0) , a Swiss-hosted cybersecurity and privacy communications platform, has closed the first tranche of its non-brokered private placement, raising gross proceeds of CA$105,000. The company issued 3 million units at CA$0.035 each, with each unit consisting of one common share and one full warrant exercisable at CA$0.05 for 24 months. No finders’ fees were paid. Sekur plans to use the proceeds to support U.S. marketing efforts for its privacy communications solutions and for general working capital.

To view the full press release, visit https://ibn.fm/nUqYi

About Sekur Private Data Ltd.

Sekur Private Data is a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure communications and secure data management. The company distributes a suite of encrypted emails, secure messengers and secure communication tools. It sells its products through its own website, approved distributors and telecommunication companies worldwide. Sekur Private Data serves consumers, businesses and governments worldwide. For more information, visit the company’s website at www.Sekur.com .

Sekur Private Data (SWISF), closed Wednesday's trading session at $0.02727, even for the day. The average volume for the last 3 months is 322,930 and the stock's 52-week low/high is $0.012/$0.064.

Datavault AI (DVLT)

TechMediaWire, SmallCapRelations, SeriousTraders, QualityStocks, MissionIR, InvestorBrandNetwork, Stocks to Buy Now, Tip.Us, StocksToBuyNow, SmallCapSociety, NetworkNewsWire, AINewsWire, StockWireNews, Jeff Bishop and Fierce Analyst reported earlier on Datavault AI (DVLT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Datavault AI (NASDAQ: DVLT) , a leader in AI data experience, valuation and monetization, has secured the majority stockholder consent required to finalize its acquisition of CompuSystems Inc. (“CSI”) and mailed an Information Statement on April 29, 2025, under Section 14(c) of the Securities Exchange Act. No stockholder vote is required, and the transaction is expected to close on or about the week of May 19. CSI’s assets and operations will be integrated into Datavault AI, with the acquisition projected to contribute $15 million to $20 million in revenue toward the company’s 2026 goal of $40 million to $50 million. CEO Nathaniel Bradley called the deal a major milestone in Datavault AI’s growth plan and said further details will be shared during a business update call scheduled for May 20 at 9 a.m. ET.

To view the full press release, visit https://ibn.fm/O0d6B

About Datavault AI Inc.

Datavault AI (Nasdaq: DVLT) is leading the way in AI experience, valuation, and monetization of assets in the Web 3.0 environment. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI’s cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange ® (IDE) enables Digital Twins, licensing of name, image, and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The company is headquartered in Beaverton, OR. Learn more about Datavault AI at www.datavaultsite.com .

Datavault AI (DVLT), closed Wednesday's trading session at $0.831, off by 1.2008%, on 197,895 volume. The average volume for the last 3 months is 1,179,957 and the stock's 52-week low/high is $0.6011/$5.889.

Silo Pharma (SILO)

QualityStocks, InvestorBrandNetwork, SmallCapRelations, MissionIR, SeriousTraders, Stocks to Buy Now, Tip.us, StocksToBuyNow, PsychedelicNewsWire, BioMedWire, SmallCapSociety, NetworkNewsWire, Small Cap Firm, StockWireNews, Fierce Analyst, StockStreetWire, Ross Givens, ProTrader, InvestorPlace, Jeff Bishop, MarketClub Analysis, OTCtipReporter, Penny Pick Finders, PennyStockScholar, Profitable Trader Authority, StockOnion, Tim Bohen, PennyStockProphet, MarketBeat, 360 Wall Street, Wealth Daily, Buzz Stocks and Premium Stock Alerts reported earlier on Silo Pharma (SILO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Silo Pharma (NASDAQ: SILO) today announced favorable preclinical results for SP-26, its novel extended-release ketamine implant aimed at treating fibromyalgia. Conducted in minipigs, the study met all endpoints, including safety, tolerability, and pharmacokinetics, with no implant-related adverse events and sustained ketamine release for up to 22 days. CEO Eric Weisblum said the results support SP-26’s advancement as a next-generation, abuse-deterrent pain therapy. Designed for subcutaneous delivery, SP-26 avoids the dissociative effects of IV ketamine and may offer a safer alternative to opioids, potentially becoming the first at-home injectable ketamine-based therapeutic.

To view the full press release, visit https://ibn.fm/APuat

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions and central nervous system (“CNS”) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug-delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting post-traumatic stress disorder (“PTSD”) and stress-induced anxiety disorders. SP-26 is a time-release, ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (“MS”). Silo’s research and development programs are conducted through collaborations with universities and independent laboratories. For more information about the company, visit www.SiloPharma.com .

Silo Pharma (SILO), closed Wednesday's trading session at $0.75, off by 7.4074%, on 1,004,271 volume. The average volume for the last 3 months is 309,999 and the stock's 52-week low/high is $0.71/$4.5.

The QualityStocks Company Corner

Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF)

The QualityStocks Daily Newsletter would like to spotlight Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF).

Nicola Mining (TSX.V: NIM) (OTCQB: HUSIF) is a junior resource company focused on monetizing high-grade mineral assets in British Columbia. The company leverages a unique dual-pronged operational strategy combining solid revenues from its wholly owned, state-of-the-art gold and silver mill with the long-term upside of 100%-owned copper, silver, and gold exploration projects. This approach allows the company to fund ongoing development while minimizing equity dilution. Nicola Mining has selected IBN , a multifaceted financial news and publishing company serving private and public entities, to spearhead its corporate communications efforts. As part of the client-partner relationship, IBN will generate greater awareness for Nicola Mining by leveraging its investor-focused distribution network, which includes over 5,000 key syndication outlets various newsletters social media channels , and wire services via InvestorWire , along with blogs and other outreach tools.

To view the full press release, visit https://ibn.fm/b7VwH

Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) is a junior resource company focused on monetizing high-grade mineral assets in British Columbia. With a unique dual-pronged model, the company combines solid operational revenues from its wholly-owned, state-of-the-art gold and silver mill with the long-term upside of 100%-owned copper, silver, and gold exploration projects. This approach allows Nicola to fund ongoing development while minimizing equity dilution.

The company’s strategy centers on aligning infrastructure and permitting advantages with mineral-rich geology, positioning it to process its own, as well as third-party high-grade gold and silver mines via partnerships, to advance its own exploration targets. Key agreements with gold producers and concentrating sales contracts provide stable cash flow, making Nicola rare among juniors in its ability to internally support growth. Its solid balance sheet and business acumen have allowed it to take stakes in other near-term gold producers, including a 75% economic stake in Dominion Gold, which commences a bulk sample in 2H 2025.

Nicola is leveraging its platform of permitted infrastructure, strategic project locations, and deep technical expertise to build shareholder value in a low-risk, high-reward framework. The company is headquartered in Vancouver, British Columbia.

Projects

Nicola Mining’s project portfolio includes high-grade copper, silver, and gold assets located in mineral-rich regions of British Columbia. Each project is 100%-owned or majority-controlled, with strong exploration potential and the necessary permits to advance development.

New Craigmont Copper Project

Nicola’s flagship asset, the New Craigmont Project, is a historic producer of over 900 million pounds of copper. Since acquiring 100% ownership in 2015, the company has drilled over 18,000 meters and identified significant skarn-hosted and porphyry-style mineralization. Recent drilling in 2024 confirmed 52.9 meters at 1.03% Cu (Hole NC-24-002), supporting the presence of a large-scale copper system. The project benefits from paved road access, connection to BC Hydro’s grid, and proximity to urban centers.

Treasure Mountain Silver Project

This 100%-owned past-producing mine has a Major Mines permit (M-239) and an NI 43-101 compliant resource estimate. The site includes multiple silver-lead-zinc veins and is permitted to extract up to 60,000 tonnes annually. Nicola is evaluating potential reactivation or joint venture options. Resource estimates include indicated resources of 52,000 tonnes grading 18.1 oz/t Ag, 3.26% Pb, and 3.4% Zn, and inferred resources of 161,000 tonnes grading 22.0 oz/t Ag, 2.48% Pb, and 3.86% Zn.

Dominion Creek Project (Au-Ag)

Nicola holds a 50% land ownership and 75% economic stake in this gold-silver project. Located 43 km from Wells, British Columbia, the site has returned grab samples averaging 61.3 g/t Au and 173.7 g/t Ag. The company has received its final permit and plans to extract a 10,000-tonne bulk sample in 2025, which will be processed at its Merritt Mill facility.

Operations

In addition to its exploration assets, Nicola Mining operates a suite of permitted industrial facilities in British Columbia that generate revenue and support the company’s broader development strategy. These assets form the backbone of Nicola’s self-sustaining business model.

Merritt Mill & Tailings Facility

Nicola owns and operates British Columbia’s only provincially permitted toll mill for gold and silver, a $30 million flotation facility located near Merritt. Gold production began in 2023. The facility is supported by long-term Milling and Profit Share Agreements with companies including Osisko Development Corporation, Blue Lagoon Resources, and Talisker Resources.

Sand & Gravel Pit / Rock Quarry / Ready-Mix Concrete Plant

Nicola also operates a permitted gravel pit (100,000 t/year), rock quarry (1,500 t/day), and is set to launch a ready-mix cement plant in Q2 2025. These operations, run in partnership with local First Nations, generate stable cash flow to support exploration efforts.

Market Opportunity

Nicola Mining is uniquely positioned in southern British Columbia, a jurisdiction recognized for its mining-friendly policies, skilled labor force, and robust infrastructure. The New Craigmont Project is geologically situated within the Guichon Creek Batholith, a region hosting some of Canada’s largest copper mines, including Highland Valley. Exploration data from 2023 and 2024 support the potential presence of both skarn and porphyry systems, increasing the strategic value of Nicola’s holdings.

The company’s other assets, including Treasure Mountain and Dominion Creek, are located in historically productive areas with high-grade mineralization and established access routes. Dominion Creek, in particular, sits atop the Isaac Lake Fault system—identified in British Columbia’s RGS (Regional Geochemical Survey) as a highly anomalous gold-silver corridor. Nicola’s integrated production model enables it to generate revenue while advancing these exploration programs without excessive dilution, providing a distinct advantage in a volatile commodities market.

Leadership Team

Peter Espig, Chief Executive Officer & Director, is a former diamond driller who spearheaded Nicola through a restructuring into its recent growth. He brings over $2 billion in private equity transaction experience, is a pioneer of SPACs, and has held senior positions at Goldman Sachs Japan and Olympus Capital.

Will Whitty, VP of Exploration, brings to the company over 15 years of experience in copper and gold exploration. He previously worked at Freeport-McMoRan and Nevada Gold Mines. He holds a master’s degree from the Mineral Deposit Research Unit (MDRU) at the University of British Columbia.

Bill Cawker, Corporate Development, manages investor relations, communications, and corporate governance. He joined Nicola in 2023 and brings extensive small-cap public markets experience, along with a degree in economics from the University of British Columbia.

Sam Wong, Chief Financial Officer, is a CPA with over 18 years of experience in the mining sector. He previously held executive roles at several publicly listed resource companies. He began his career at Deloitte LLP in Vancouver.

Investment Considerations
  • High-Grade Copper Opportunity: 100% ownership of the New Craigmont Project, one of British Columbia’s most promising high-grade copper exploration targets, strategically located adjacent to Canada’s largest copper mine (Highland Valley Copper).
  • Immediate Revenue Generation: Operates British Columbia’s only permitted mill capable of processing third-party gold and silver ore, with current throughput supporting strong, near-term cash flow.
  • Diverse Revenue Streams: Revenue growth fueled by commercial milling operations, gold concentrate sales, and active aggregate production — providing self-funded exploration and reducing reliance on capital raises.
  • Strategic Location & Infrastructure: Centrally located near major transportation routes and mining services, providing cost advantages and operational efficiencies.
  • Proven Leadership Team: Led by a management group with extensive track records in mining operations, project development, and capital markets, driving disciplined growth and long-term value creation.

Nicola Mining Inc. (OTCQB: HUSIF), closed Wednesday's trading session at $0.27, up 2.6878%, on 2,500 volume. The average volume for the last 3 months is 77,190 and the stock's 52-week low/high is $0.1498/$0.3024.

Recent News

ONAR Holding Corp. (OTCQB: ONAR)

The QualityStocks Daily Newsletter would like to spotlight ONAR Holding Corp. (OTCQB: ONAR).

Onar (OTCQB: ONAR) , a marketing technology company and network of agencies, has released its 2024 shareholder letter outlining strong financial growth, global expansion, and tech-driven initiatives. CEO Claude Zdanow reported a 57% increase in consolidated revenue over the first nine months of the year and a $250,000 reduction in cost of revenues. The company strengthened its position through a strategic partnership with iQSTEL (OTCQX: IQST), workforce expansion across five continents, and the launch of ONAR Labs to pioneer innovations in AI, machine learning, and analytics. The letter also confirmed plans for a strategic acquisition and the formation of an independent board in 2025.

To view the full article, visit https://ibn.fm/pkaDP

ONAR Holding Corp. (OTCQB: ONAR) is a leading marketing technology company and marketing agency network focused on delivering integrated, AI-driven solutions to accelerate revenue growth for its clients. Through an agile agency network specializing in performance marketing, full-service healthcare marketing, experiential marketing, and technology incubation, ONAR provides best-in-class services to a growing roster of clients worldwide.

Built on a foundation of innovation and operational excellence, ONAR’s vision is to redefine marketing services by leading with technological advancement. With employees across five continents, the company is aggressively expanding its team to support both organic growth and an active acquisition pipeline. ONAR’s strategic growth model focuses on growing and acquiring proven agencies under one umbrella to deliver superior service offerings across industries.

ONAR’s mission is to drive measurable client success through integrated, high-impact marketing solutions that blend creativity, data science, and technology. As it continues to expand, ONAR is focused on building a global marketing services network that serves companies ranging from $10 million to $300 million in revenue.

The company is headquartered in Miami, Florida.

Portfolio

ONAR’s operations are organized across a network of specialized agencies that together serve more than 45 clients across a wide range of industries. Each agency brings deep domain expertise and a results-driven approach:

  • Storia: A premier performance marketing agency specializing in brand growth, paid media, and SEO. With a focus on data-driven excellence, Storia delivers highly targeted marketing strategies that maximize ROI across digital platforms. The agency partners with leading brands to drive measurable revenue outcomes and long-term brand equity.
  • Of Kos: A full-service healthcare marketing agency committed to redefining the patient experience. Of Kos partners with healthcare professionals to deliver integrated campaigns that not only increase patient engagement but also elevate the standard of care across the healthcare landscape. Its work bridges marketing innovation and healthcare expertise to create real impact.
  • CHALK: An experiential marketing agency that transforms bold ideas into unforgettable, immersive experiences. CHALK’s team of event architects specializes in designing events that break boundaries — from brand activations and pop-ups to major corporate experiences — creating lasting emotional connections between brands and audiences.
  • ONAR Labs: The company’s pioneering technology incubator, ONAR Labs, brings together data scientists, engineers, and industry experts to develop proprietary marketing technologies. Every product is rigorously battle-tested within the agency network before commercialization, ensuring that ONAR Labs delivers real-world solutions that enhance marketing performance and client success.

Market Opportunity

ONAR operates at the intersection of marketing services and marketing technology, two sectors undergoing rapid evolution and expansion. The global digital marketing software market alone is projected to reach $264.15 billion by 2030, expanding at a CAGR of 19.4%, according to Grand View Research. Meanwhile, healthcare marketing and experiential marketing are experiencing renewed momentum, as companies seek to create more personalized and immersive customer experiences.

With its integrated, AI-driven platform and expertise across multiple high-growth verticals, ONAR is well positioned to capture a growing share of the marketing spend from mid-sized to large enterprise clients. As businesses increasingly prioritize digital transformation, customer experience, and data-driven marketing, ONAR’s diversified offerings and proprietary technologies through ONAR Labs create meaningful competitive advantages in a highly fragmented market.

Leadership Team

Claude Zdanow, Chief Executive Officer, is a seasoned entrepreneur and business leader with deep experience scaling service organizations and technology platforms. Prior to founding ONAR, he built and successfully exited multiple companies in marketing and media, combining creative vision with operational discipline to drive measurable client growth.

Chris Becker, President, brings extensive operational and strategic expertise to ONAR, focusing on driving agency performance and expanding the company’s integrated service offering. His leadership emphasizes operational rigor, client success, and scaling the company’s footprint across industries and regions.

Patricia Kaelin, Chief Financial Officer, oversees ONAR’s financial operations and strategic planning. A distinguished financial executive with more than 25 years of experience in scaling high-growth companies and leading finance teams at both public and private companies, she expertly manages financial strategy, M&A transactions, and provides a strong foundation for ONAR’s continued expansion and acquisition initiatives.

Sam Mendez, Chief of Staff, fosters seamless collaboration across the organization. She expertly manages strategic projects, facilitates clear communication channels, and acts as a key point of contact to maximize the executive team’s impact and advance organizational goals.

Investment Considerations
  • ONAR is scaling a diversified, AI-driven marketing network addressing multiple high-growth industry verticals.
  • The company is actively pursuing an acquisition-driven expansion strategy to grow its marketing agency network.
  • ONAR Labs provides a proprietary technology pipeline, offering additional revenue streams beyond traditional marketing services.
  • A strong leadership team with proven track records in business growth, financial management, and technology commercialization positions the company for long-term success.
  • ONAR’s focus on middle market and growth-stage clients aligns with sectors expected to see a sustained rise in marketing spend over the next decade.

ONAR Holding Corp. (OTCQB: ONAR), closed Wednesday's trading session at $0.0369, off by 5.3846%, on 31,014 volume. The average volume for the last 3 months is 34,140 and the stock's 52-week low/high is $0.03/$0.167.

Recent News

Nutriband Inc. (NASDAQ: NTRB)

The QualityStocks Daily Newsletter would like to spotlight Nutriband Inc. (NASDAQ: NTRB).

Sheridan was recently named as a finalist for the 2025 EY Entrepreneur of the Year Awards

The CEO's international perspective and expertise were further validated when he was featured in a recent BBC News article

Chairman Serguei Melnik also participated in a market interview where he spoke about Nutriband's mission, achievements and plans for the future

Nutriband (NASDAQ: NTRB) is earning widespread recognition for the board's leadership, expertise and innovation across a variety of platforms. Sheridan has recently been acknowledged in several high-profile ways that affirm his growing influence as a respected professional in the healthcare and business sectors. From being named a finalist for the prestigious EY Entrepreneur of the Year Awards to providing key insights in a BBC News feature on Irish companies operating internationally and sharing their strategic vision in a wide-ranging interview, NTRB's voice is increasingly shaping discussions around entrepreneurship, innovation and the future of healthcare.

Nutriband (NASDAQ: NTRB) has released a shareholder letter from CEO Gareth Sheridan outlining key achievements in 2024 and plans for 2025, centered on advancing its AVERSA abuse-deterrent transdermal technology. The company is transitioning from feasibility to commercial development of AVERSA Fentanyl in partnership with Kindeva Drug Delivery, targeting a pivotal Human Abuse Liability clinical trial and NDA filing. AVERSA Fentanyl and AVERSA Buprenorphine could reach peak annual sales of up to $200 million and $130 million respectively. Nutriband also expanded its global patent portfolio to 46 countries and raised $8.4 million in a non-brokered placement. The company expects continued revenue growth in 2025 from its Pocono Pharma subsidiary, driven by its partnership with KT Tape.

To view the full article, visit https://ibn.fm/NGtih

Nutriband Inc. (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA™ technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China, with recent extensions into Macao.

The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.

Nutriband has three subsidiaries, including 4P Therapeutics, its clinical and regulatory subsidiary; Pocono Pharmaceutical, a contract manufacturer for a wide range of clients; and Active Intelligence, a developer of sports recovery products. This ownership of manufacturing and clinical development capabilities drastically reduces costs for AVERSA and other technologies.

In April 2024, Nutriband announced that the company had been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband’s wholly owned Active Intelligence subsidiary will act as manufacturer.

In February 2025, the company formalized its product development partnership with Kindeva Drug Delivery through a long-term exclusive agreement. The collaboration supports the commercial pathway for AVERSA Fentanyl by leveraging Kindeva’s FDA-approved transdermal fentanyl patch system.

The company is headquartered in Orlando, Florida.

Products

Nutriband’s lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal patch. The company announced in March 2024 that it will submit a New Drug Application to the U.S. Food and Drug Administration seeking approval to market AVERSA Fentanyl. In subsequent updates, Nutriband confirmed that the NDA submission remains the company’s primary focus and is backed by a strong cash position.

Nutriband has partnered with Kindeva Drug Delivery, a leading global contract development and manufacturing organization, to incorporate Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. Because Nutriband’s abuse-deterrent technology is incorporated into the fentanyl patch but is physically separate from and does not come in contact with the drug layer, the clinical trials typically needed to demonstrate safety and efficacy for a new drug formulation would not be required.

In support of this commercialization strategy, Nutriband closed an $8.4 million private placement in April 2024 to fund development activities related to AVERSA Fentanyl. The company also licensed Bitrex®, a widely used aversive agent, to enhance the deterrent profile of its patch formulation.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The company plans to seek an expedited review by the FDA, as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

Nutriband’s AVERSA product development pipeline also includes abuse deterrent versions of currently approved and marketed transdermal patches containing buprenorphine, an opioid used to treat opioid use disorder, and methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD). Both are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.

Market Opportunity

Nutriband cites a market analysis report from Boston-based Health Advances, a healthcare and life sciences consulting firm. According to the report, upon FDA approval, AVERSA Fentanyl has the potential to reach peak annual sales of $200 million in the U.S.

The company further states that, should non-abuse-deterrent transdermal fentanyl products lose FDA marketing approval, AVERSA Fentanyl would have greater pricing flexibility and would have the potential to generate more than $500 million in annual revenue.

Management Team

Gareth Sheridan is Co-Founder and CEO of Nutriband. He was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband. He has worked as a Business Mentor with 100 Minds, a social enterprise that brings together some of Ireland’s top college students and connects them with a cause to achieve large charitable goals. He received a B.Sc. in Business and Management from Dublin Institute of Technology.

Serguei Melnik is Co-Founder and President of Nutriband. He has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial frameworks for operations of foreign companies in the U.S. He previously was the COO of Florida-based Asconi Corporation. He also was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,” in Chisinau, Moldova, and prior to that practiced law in Moldova. He is fluent in four languages.

Jeff Patrick, Pharm.D., is Chief Scientific Officer of Nutriband. He currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center. His prior roles included Global Vice President at Mallinckrodt Pharmaceuticals Inc.; and roles at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo Inc. He was a clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy.

Gerald Goodman is CFO of Nutriband. He is a certified public accountant with his own firm, Gerald Goodman CPA. He also practiced with Madsen & Associates, CPAs, and was a partner in the accounting firm of Wiener, Goodman & Company. He is also a director of Lifestyle Medical Network Inc., which provides management services to healthcare providers. He is a graduate of Pennsylvania State University, where he received a bachelor’s degree in accounting.

Investment Considerations
  • Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, like fentanyl, while keeping these drugs accessible to patients.
  • AVERSA technology can be incorporated into any transdermal patch.
  • The company has a broad and expanding intellectual property portfolio protecting AVERSA, with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China.
  • Nutriband closed an $8.4 million financing round in April 2024 to support commercial development of AVERSA Fentanyl, its abuse-deterrent fentanyl transdermal patch.
  • In February 2025, the company formalized a long-term exclusive partnership with Kindeva Drug Delivery to support AVERSA Fentanyl’s pathway to market.

Nutriband Inc. (NASDAQ: NTRB), closed Wednesday's trading session at $6.88, up 21.1268%, on 5,405 volume. The average volume for the last 3 months is 38,718 and the stock's 52-week low/high is $3.3/$11.78.

Recent News

Platinum Group Metals Ltd. (TSX: PTM) (NYSE American: PLG)

The QualityStocks Daily Newsletter would like to spotlight Platinum Group Metals Ltd. (TSX: PTM) (NYSE American: PLG).

The price of gold has been setting record after record and many investors are now wondering whether the price of an ounce of this precious metal could reach $4,000 this year. After all, it reached $3,000 in March, and now seems to be comfortable at the $3,300 level with no sign of a major drop. We explore what the prospects of this metal are in 2025 and beyond. Geopolitical instability, economic uncertainty and constantly shifting market conditions have all played a part in driving up the price of gold. In such situations, investors flock to safe haven assets, and gold leads the pack of safe haven assets. It should be noted that the price jump seen in April coincided with a significant dip on stock exchanges. This means that a lot of people who don't normally participate in the gold market flocked in from the stock exchange. The market for gold broadened and could change if other assets regain their allure. For now, gold is in the limelight, and the current market conditions could be valuable tailwinds for gold-mining companies like Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM).

Platinum Group Metals (NYSE American: PLG) (TSX: PTM) is featured in the latest episode of The MiningNewsWire Podcast, where Co-Founder, Director, President and CEO Frank R. Hallam discusses the company's flagship Waterberg Project in South Africa. Hallam highlights how the deposit—discovered in 2011—stands apart with its shallow depth and exceptional thickness, enabling safer, more cost-efficient, and highly mechanized mining. Unlike traditional South African platinum operations that rely on deep, labor-intensive shafts, Waterberg allows for decline access and heavy machinery. Hallam also shares insights on Lion Battery Technologies, the company's joint venture exploring platinum and palladium applications in lithium batteries, as part of Platinum Group Metals' innovation strategy.

To view the full press release, visit https://ibn.fm/dqBDH

Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) is the operator of the Waterberg Project, a bulk underground platinum group metals (PGM) deposit discovered by Platinum Group in 2011 and located on the Northern Limb of the Bushveld Complex in South Africa. The Waterberg Project is planned as a fully mechanised platinum, palladium, rhodium and gold mine, including by-product copper and nickel production, and is projected to be one of the largest and lowest cost PGM mines globally.

The project is a joint venture between Platinum Group; integrated PGM producer Impala Platinum Holdings Ltd. (OTCQX: IMPUY); Japanese consortium HJ Platinum, which includes trading house Hanwa Co. and the government-backed Japan Organization for Metals and Energy Security (JOGMEC); and local empowerment partner Mnombo Wethu Consultants (Pty) Ltd. Platinum Group has an effective 50.22% interest in the Waterberg Project.

The company’s primary business objective is to advance the Waterberg Project to a development and construction decision. An update to the 2019 Definite Feasibility Study is expected in 2024.

PGMs are essential and precious metals that include platinum, palladium, rhodium, iridium, osmium and ruthenium. These metals are known for their purity, high melting points and unique catalytic properties. They are utilized in a number of industrial processes, technologies and commercial applications and play a critical role in autocatalysis and pollution control in the automotive sector. The bulk of global PGMs are mined in Southern Africa and Russia.

The unique properties of PGMs are being applied to various technologies as possible solutions for more efficient energy generation and storage, which may create new demand for PGMs. The company’s battery technology initiative through Lion Battery Technologies Inc., using platinum and palladium in lithium battery technologies, represents one such new opportunity in the high-profile lithium battery research and innovation field.

Platinum Group Metals Ltd. founded Lion Battery Technologies Inc. in partnership with Anglo American Platinum Ltd. (AMS: JNB) to support the use of palladium and platinum in lithium battery applications. Lion Battery has entered into an agreement with Florida International University to further advance a research program that uses platinum and palladium to unlock the potential of Lithium Sulfur (Li-S) battery chemistries.

Platinum Group is headquartered in Vancouver, B.C., and Johannesburg, South Africa.

Waterberg Project

Platinum Group’s sole material mineral property, the Waterberg Project, is presently in process with pre-construction permitting; engineering work, including road upgrade and traffic studies; finalization of power and water infrastructure design; and construction camp design.

The company’s principal product from the Waterberg Project is planned to be a PGM-bearing concentrate. The concentrate will contain economic amounts of six elements comprising platinum, palladium, rhodium, gold, copper and nickel. The company’s partner in the Waterberg Project, Impala Platinum Holdings, has acquired a right of first refusal to enter into an offtake agreement, on commercial arm’s-length terms, for the smelting and refining of mineral products from the Waterberg Project.

The Waterberg project has proven and estimated reserves of 19.5 million ounces of PGMs and gold. When fully operational, the mine is projected to produce more than 400,000 ounces of PGMs annually during the peak period of steady state production. The life of the mine is projected at 45 years.

South Africa’s PGM mining sector remains closely tied to economic developments in the global automotive industry, which in 2022 accounted for approximately 43% of the total global demand for platinum and 82% of the total global demand for palladium.

Market Opportunity

According to a report from Straits Research, a global market and business research firm, the worldwide platinum market had an estimated value of $7.72 billion in 2022 and is projected to reach $11.95 billion by 2031. That represents a CAGR of 5.13% over the forecast period.

Platinum, one of the rarest of precious metals, is about 30 times scarcer than gold. It is crucial to the automotive and electronics industries and is also used to make jewelry. Stricter emissions regulations around the world have led to an increased demand for platinum to be used in catalytic converters to reduce automotive emission, the report states.

A report from Allied Market Research estimated the global palladium market at $16.3 billion in 2021 and projects the market will reach $28.6 billion by 2031, growing at a CAGR of 5.8% over the period.

Palladium is also used in automotive catalytic converters for reducing emissions and in jewelry, dentistry, watchmaking, blood sugar test strips, aircraft spark plugs, surgical instruments, electrical contacts and musical instruments.

An increase in demand for consumer electronics has driven demand for palladium-based multilayer ceramic capacitors (MLCC) used to store energy in electronic devices such as broadcasting equipment, mobile telephones, computers, electronic lighting and high voltage circuits, according to the report.

Management Team

Frank R. Hallam is Co-Founder, Director, President and CEO of Platinum Group. He has over 30 years of experience in the mining, minerals and petroleum industry as an operator, principal and founder. He was a co-founder and former CFO of MAG Silver Corp. He was also co-founder and director of West Timmins Mining Inc. and a director of Lake Shore Gold Corp. In addition, he was CFO and director with gold exploration company Tan Range Exploration Corp. He is a Chartered Professional Accountant and was formerly an auditor in the public mining practice of PwC. He holds a Bachelor of Business Administration from Simon Fraser University.

Greg Blair is CFO of Platinum Group. He has been with Platinum Group since 2010 in various roles, most recently as Interim CFO. Prior to joining Platinum Group, he was at a public accounting firm working on public company (mainly mining) audits. He is a Chartered Professional Accountant and holds a degree in Economics from Simon Fraser University and has completed the Canadian Securities Course.

Kris Begic is VP Corporate Development of Platinum Group. He has over 25 years of experience in the mining industry and capital markets and has been involved with the raising of over $500 million for various exploration and development projects globally. His efforts are focused on project generation, mergers and acquisitions, capital markets, investor relations and marketing.

Platinum Group Metals Ltd. (NYSE American: PLG), closed Wednesday's trading session at $1.2, up 0.8403361%, on 278 volume. The average volume for the last 3 months is 731,617 and the stock's 52-week low/high is $0.99/$2.27.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

A team of researchers has leveraged a technique called temporal learning to train an AI system to predict the likelihood of brain cancer recurring in kids diagnosed with gliomas. This AI model uses the magnetic resonance images periodically captured after the kids have received treatment for the gliomas. The study's findings, based on analyzing multiple images, indicate that the AI model can produce predictions that are 89% accurate when compared to predictions made on the basis of just one image that have an accuracy rate of 50%., no different from flipping a coin. The data from the study shows that the model could provide a recurrence prediction 12 months before it actually happened, which was superior to the AI models that relied on only one MRI image. The researchers say this model still requires further validation and clinical study before its efficacy can be confirmed. Its success could enable patients to start treatment early before recurrent gliomas progress. Catching the recurrence early would also increase the success odds of brain tumor treatments that companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are working to bring to market.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $1.085, up 5.3398%, on 4,432 volume. The average volume for the last 3 months is 214,441 and the stock's 52-week low/high is $0.7715/$800.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

OpenAI, the company behind ChatGPT, has shown interest in acquiring Chrome—the world's most widely used web browser—if Google were ever required to sell it. Nick Turley, a senior OpenAI executive, revealed this during testimony supporting the U.S. government's antitrust case against Google. The U.S. Department of Justice (DOJ) argues that Google has an unfair hold over the online search market and is pushing for the company to be broken apart. Google, on the other hand, insists that Chrome is not on sale and is seeking to have the lawsuit dismissed. Altman and Musk were once collaborators at OpenAI, but their relationship soured years ago due to disagreements over the company's future. Meanwhile, Musk's X now features its own AI system called Grok, integrated directly into the social media site.

The outcomes of these court cases are likely to be followed by numerous AI companies like D-Wave Quantum Inc. (NYSE: QBTS) as they could reshape the trajectory of corporate America and the world.

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Wednesday's trading session at $6.91, off by 1.2857%, on 763,933 volume. The average volume for the last 3 months is 33,311,455 and the stock's 52-week low/high is $0.7505/$11.95.

Recent News

Calidi Biotherapeutics Inc. (NYSE American: CLDI)

The QualityStocks Daily Newsletter would like to spotlight Calidi Biotherapeutics Inc. (NYSE American: CLDI).

Cancer statistics underscore the urgency of ongoing cancer research and the need for more effective cancer treatments.

Calidi Biotherapeutics has announced preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors.

The trials show an ability to deliver therapeutic payloads with precision while simultaneously attacking tumors.

Cancer remains one of the deadliest diseases worldwide. Globally, the World Health Organization reports that the number of deaths will surpass 9.7 million in 2024, with a projected 20 million new cancer cases diagnosed; WHO also noted that it anticipates the cancer burden increasing an estimated 77% by 2050 (https://ibn.fm/VfZlY). These numbers underscore the urgency of ongoing cancer research and the need for more effective cancer treatments. This is where cutting-edge innovations, such as those pioneered by Calidi Biotherapeutics (NYSE American: CLDI), come into play. Calidi Biotherapeutics recently announced promising preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors (https://ibn.fm/bbPdB). This novel platform has demonstrated an impressive ability to successfully deliver therapeutic agents to tumor cells while minimizing damage to surrounding healthy tissues. By targeting tumors more effectively, this approach holds the potential to significantly improve treatment outcomes and reduce side effects.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering proprietary technology that empowers the immune system to combat cancer. Calidi’s innovative, off-the-shelf cell-based platforms use allogeneic stem cells to deliver potent oncolytic viruses (OVs) across multiple oncology indications, including high-grade glioma (brain cancers) and solid tumors. In addition, Calidi has presented a breakthrough systemic technology, RTNova, which utilizes an exteracellular enveloped virotherapy. RTNova is pre-clinical and has been extremely well-received by market analysts and large-cap biopharma – opening the door for potential collaboration.

These cell-based platforms are engineered to protect, amplify, and enhance the efficacy of oncolytic viruses, resulting in improved patient safety and potentially advancing treatment outcomes for metastatic disease. By employing a dual approach that combines OV delivery with immune activation, Calidi’s therapies aim to not only treat but potentially prevent the spread of metastatic cancers.

The company’s development pipeline leverages this technology to address pressing needs in cancers such as glioblastoma (brain cancer), metastatic melanoma, triple-negative breast cancer, head & neck cancer, and lung cancer. Calidi’s approach has shown early signals of efficacy and safety, establishing it as a distinctive player in the growing OV market, which is projected to increase significantly in value over the next decade.

Calidi is headquartered in San Diego, California.

Products

Calidi’s product pipeline includes advanced cell-based platforms targeting a variety of oncology indications, each designed to harness the power of oncolytic virotherapy for improved cancer treatment outcomes.

  • NeuroNova (CLD-101): A platform designed for treating high-grade gliomas (HGG), NeuroNova employs neuronal stem cells combined with an engineered adenovirus (CRAD-s-Pk7) to selectively target glioma cells. After a successful Phase 1 safety study in newly diagnosed HGG, NeuroNova has now progressed into Phase 1/1b trials for recurrent cases. FDA clearance for a Phase 1b/2 trial at Northwestern University was received in September 2024, with patient enrollment expected to begin in Q1 2025. This trial will utilize multiple-dose intracerebral administration to maximize safety and efficacy in newly diagnosed HGG patients.
  • SuperNova (CLD-201): Built on Calidi’s foundational technology, SuperNova utilizes an engineered Vaccinia virus (CAL1) delivered via allogeneic adipose-derived mesenchymal stem cells to target advanced solid tumors, including head & neck, triple-negative breast cancer, and soft tissue sarcomas. Early studies with autologous stem cells demonstrated both safety and promising efficacy, and Calidi plans to begin a Phase 1 trial with multiple dose regimens for SuperNova in the coming months.
  • RTNova (CLD-400): Calidi’s systemic delivery platform for lung and metastatic cancers, RTNova employs an extracellular enveloped virotherapy (envRT-01) technology for intravenous (IV) administration, simplifying the treatment process and expanding its potential applications. Currently in preclinical stages, RTNova focuses on demonstrating efficacy and safety through systemic administration. A clinical trial targeting metastatic lung cancer is anticipated for Q2 2026, using a single-arm monotherapy with dose escalation. Calidi has partnered with SIGA Technologies (NASDAQ: SIGA) to support the development of this program.

Market Opportunity

The global oncology drugs market was valued at $201.75 billion in 2023 and is projected to grow to $518.25 billion by 2032, with a CAGR of 11.3%. The oncolytic virotherapy market in particular is growing rapidly, driven by increasing approval rates and significant unmet needs.

The market for OV treatments is expected to expand from one approved product generating $150 million in the U.S. in 2021 to 6-8 approved therapies generating $2.4 billion by 2030. As a leader in OV technology, Calidi is well-positioned to address these high-demand areas in oncology.

Alongside global trends, the American Cancer Society projects nearly two million new cancer diagnoses in the U.S. in 2024, reflecting a 28% increase since 2010. This underscores the urgent need for novel therapies that not only treat disease progression but also enhance patient quality of life, reinforcing the demand for Calidi’s innovative approaches.

Management Team

Allan Camaisa, CEO, Chairman, and co-founder, is a seasoned leader with extensive experience in scaling businesses to successful exits. Mr. Camaisa previously led High Technology Solutions, growing it from two employees to over 500 with $50 million in revenue. He also served as CEO of Parallel6 Inc. and is a U.S. Naval Academy graduate with further studies at Harvard Business School.

Antonio Santidrian, Ph.D., Chief Scientific Officer, leads all research and development initiatives at Calidi and is the coinventor of the company’s CLD-201 (Supernova) and CLD-400 (RTNova) platforms. Since joining Calidi in 2015, he has applied his 20+ years of expertise in academia and biotech, focusing on anti-cancer translational research, to drive the company’s innovative drug pipeline. Before Calidi, Dr. Santidrian led translational studies at The Scripps Research Institute, advancing treatments for breast cancer metastasis, and contributed to the development of ACADRA for chronic lymphocytic leukemia (CLL) at the University of Barcelona, Spain.

Boris Minev, M.D., President of Medical and Scientific Affairs, is a renowned physician-scientist with expertise in Immuno-Oncology, stem cell biology, and oncolytic viruses. Previously, Dr. Minev served as Director of Immunotherapy and Translational Oncology at Genelux Corporation and remains an adjunct professor at the Moores UCSD Cancer Center. His background includes research at the National Cancer Institute.

Andrew Jackson, CFO, has held executive finance roles with experience in biotech and clinical-stage companies, including Eterna Therapeutics and Ra Medical Systems. Mr. Jackson holds an MSBA in Finance from San Diego State University and a BSB in Accounting from the University of Minnesota.

Calidi Biotherapeutics Inc. (NYSE American: CLDI), closed Wednesday's trading session at $0.4825, off by 2.3082%, on 234 volume. The average volume for the last 3 months is 345,947 and the stock's 52-week low/high is $0.35/$4.9.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Switching to an electric car often seems like an incredibly costly endeavor. The average battery electric vehicle (BEV) costs around $10,000 to $15,000 more than a comparable gasoline-powered car, and most EV owners also install home chargers, making the initial price of electric vehicle ownership significantly higher. Fortunately, switching your gas-powered car for an electric alternative can save you a surprising amount of money over time. A report from Payless Power provides an outline of the average cost savings a driver can expect by transitioning to an electric car. Washington offers the highest electric vehicle-related savings, with drivers saving up to $18,055 over 10 years thanks to state financial incentives. Nevada is second with an estimated $15,726, followed by Oregon ($14,481) and Alaska ($13,933). Alaska's inclusion at the top of the list is surprising, as its cold climate impacts EV performance and does not typically support electric vehicle ownership as well as milder states. Although this estimate focuses primarily on fueling versus charging costs, it highlights the strong financial case for switching to an electric car. For many drivers, these savings, combined with EV-related perks like instant acceleration and quieter driving, have made electric cars an obvious and appealing choice. As the public becomes more aware about these cost-savings, the market penetration of various EV makers like Mullen Automotive Inc. (NASDAQ: MULN) is bound to tick upwards over the coming years.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Wednesday's trading session at $0.39, off by 20.3106%, on 856,345 volume. The average volume for the last 3 months is 3,949,912 and the stock's 52-week low/high is $0.35/$4710000.

Recent News

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)

The QualityStocks Daily Newsletter would like to spotlight ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF).

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) is a fully permitted, pre-production resource company on a clear path to near-term gold and silver production. With established infrastructure in place and a significant gold-silver resource, the company is uniquely positioned to generate near-term cash flow while unlocking the full potential of its Montauban Gold-Silver Project in Quebec—one of the top mining jurisdictions in the world.

ESGold is building a foundation for long-term growth through a dual-track strategy: cash-flow generation from tailings reprocessing to fund district-scale exploration.

The Montauban site, which operated as a mine for over 80 years, is now undergoing its first-ever systematic exploration program to determine just how large the remaining deposit may be. Near-term cash flow from tailings reprocessing will be used to fund exploration, with the goal of increasing the resource base and uncovering new discoveries across the expansive land package.

ESGold is advancing a scalable and replicable clean extraction model that turns legacy mine sites into revenue generating assets while setting a new industry benchmark for sustainable resource recovery.

The recent completion of a C$3.4M financing has enabled ESGold to initiate the final construction phase of its mill circuit—moving the company decisively toward production of gold and silver in Q3 2025.

Montauban Gold-Silver Project: Production Imminent

Located approximately 80 kilometers west of Quebec City, the Montauban Project is a past-producing gold-silver mine with surface and underground mineralization and over 900,000 tonnes of historical tailings. ESGold has invested over C$15 million to date, building out roads, power access, and a 16,000 sq. ft. processing facility. The company recently completed a C$3.4M financing to begin final construction of the mill circuit.

The company is fully permitted to enter into production that is expected to commence in Q3 2025 with a capacity of 500 tonnes per day, scaling to 1,000 tpd. An updated Preliminary Economic Assessment (PEA) is currently underway to reflect all-time high gold prices and the anticipated upside from the near-surface resource.

Parallels Between Broken Hill & Montauban

Broken Hill, discovered in 1883 in Australia, became the world’s largest source of silver, lead, and zinc—producing over $100 billion worth of metals. What made it unique was that the richest mineral zones were hidden deep underground in a twisted, boomerang-like shape, and it took decades to fully understand just how large the deposit really was.

Geologists now believe ESGold’s Montauban Project in Quebec may share similar traits. Like Broken Hill, it contains high-grade silver, lead, and zinc, along with gold—and sits within the same type of geological system known to host large, high-value mineral deposits. The rock formations, mineral assemblages, and structural complexity all suggest that Montauban could be hiding much more than what’s been historically uncovered. Academic studies now support this possible geological parallel, pointing to further evidence suggesting Montauban was formed under similar conditions as Broken Hill.

Exploration Upside

With production on the horizon, ESGold is advancing a major exploration campaign. Montauban has never undergone systematic modern exploration.

The company is currently completing a large-scale Ambient Noise Tomography (ANT) survey—a powerful 3D imaging technology that will define the size, shape, and continuity of the mineralized system. ANT is already showing strong results, with imaging going beyond the original 400m depth target and now expected to exceed 800m. This cutting-edge technology has the potential to reveal the full extent of the anomaly for the first time in Montauban’s 110-year history.

Scalable, Replicable, Clean Mining

Montauban is also part of a broader vision. Across Canada and globally, there are hundreds of orphaned or legacy mine sites that remain unrehabilitated despite containing valuable residual metals in tailings. Quebec alone is home to more than 259 of these sites, highlighting the scale of the opportunity. ESGold is advancing a scalable and replicable clean extraction model that transforms legacy sites into productive assets while setting a new benchmark for sustainable resource recovery.

The company has also performed testing that utilizes Dundee Sustainable Technologies’ CLEVR Process™, a proprietary non-cyanide extraction method that achieved 90.9% gold recovery in lab testing. This clean processing approach remains a valuable and scalable asset supporting ESGold’s near-term production and exploration growth strategy.

As a complement to its core mining operations, ESGold is developing clean technology solutions through a joint venture with DMCMS Inc. This initiative includes a polymer division that manufactures environmentally friendly products such as road stabilizers, dust suppressants, and other industrial blends—expanding the company’s sustainable commercial footprint.

Market Opportunity

ESGold is operating in a unique and specialized segment of the mining industry—reprocessing and revitalizing legacy mine sites. The Montauban Project offers both near-term cash flow and long-term growth potential by converting tailings into revenue while systematically exploring for additional high-value mineral endowments. The company’s established infrastructure, full permitting, and reclamation approvals reduce development risk and enhance execution timelines.

The broader green mining market is projected to reach $15.92 billion by 2030, according to Grand View Research. This growth is being driven by increased demand for responsible extraction methods, ESG-aligned practices, and critical mineral security. With construction underway at its fully permitted Montauban site—and exploration advancing along a Broken Hill-type geological model—ESGold is well positioned to emerge as Canada’s next premier gold and silver producer.

Leadership Team

Paul Mastantuono, Chief Executive Officer and Director, graduated with distinction from the University of Ottawa with a bachelor’s degree in social science, concentrating in criminology. He has extensive experience in the construction and transportation industries and has worked as an independent business consultant for various companies, including DNA Precious Metals Inc.

Brad Kitchen, President and Director, brings over 35 years of experience in investment banking and senior corporate management, primarily with resource-based companies. He has a detailed knowledge of regulatory, security, and tax issues, cross-border financings, and market influences, which he has applied to address business challenges for issuers and investors. Mr. Kitchen was also CEO of Eagle Hill Exploration, the company that generated in only five years the first Bankable Feasibility Study on the Windfall Lake Gold Project that was recently sold by Osisko Mining to Gold Fields for US$1.6 billion.

Andre Gautier, Senior Geologist and Director, brings over 47 years of experience in the Mining Exploration field and has worked in over 35 countries. His work experience includes entities such as: SOQUEM, Falconbridge Ltd., Noramco and Cambior Inc. Mr. Gauthier was president of MaxyGold Corp. (China), INCA Pacific Resources Inc., Lara Exploration Ltd., and Gold Holding Ltd. Mr. Gauthier also served as a Director of Vena Resources Inc., MaxyGold Corp., Lara Exploration Ltd., Western Union Peru, and Gold Holding Ltd., and from March 2015 until 2018, he served as interim Managing Director and CEO of Gold Holding Ltd., headquartered in Dubai (UAE). He has a BSC in Geology Eng. and MSC from UQAC (Chicoutimi, Quebec) and is an active member and leader of many mining and professional organizations (Canada, Peru, UAE, and China).

Investment Considerations
  • Fully Permitted & Funded for Near-Term Production: Construction underway soon at Montauban with gold-silver production expected in Q3 2025.
  • Tailings-to-Cashflow Strategy: Near-term cash flow from processing historic tailings will fund exploration across the district-scale land package.
  • Replicable Clean Mining Model: Scalable approach to legacy mine redevelopment in Canada and globally.
  • Broken Hill Analogue: Geological and structural parallels suggest Montauban may host a larger, mineralized system at depth.
  • Modern 3D Imaging Tech: Cutting-edge ANT survey is producing subsurface imaging beyond 800m, uncovering the potential size of the deposit.

ESGold Corp. (OTCQB: ESAUF), closed Wednesday's trading session at $0.3748, up 4.8098%, on 46,451 volume. The average volume for the last 3 months is 92,330 and the stock's 52-week low/high is $0.0221/$0.5.

Recent News

Brera Holdings PLC (NASDAQ: BREA)

The QualityStocks Daily Newsletter would like to spotlight Brera Holdings PLC(NASDAQ: BREA).

Brera Holdings PLC (NASDAQ: BREA) is an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach. The company capitalizes on opportunities to earn tournament prizes, secure sponsorships, collect transfer fees, provide professional sports consulting services, and enhance the valuation of its clubs.

Brera Holdings builds on the legacy of Brera FC, an international football club (referred to as soccer in the U.S.), that it acquired in July 2022. Established in 2000 and based in Milan, Italy, Brera FC has distinguished itself by cultivating an alternative football legacy. In October 2024, the Internet Marketing Association awarded Brera FC with the Social Impact Through Soccer accolade at its IMPACT 5050 Conference, recognizing the club’s global perspective and positive contributions to society.

The company’s growth strategy focuses on unlocking value from undervalued sports clubs and talent, driving innovation, and generating socially impactful outcomes. Brera Holdings is actively expanding its Global Sports Group, acquiring professional football and other sports clubs in emerging markets such as Africa, Asia, and Europe.

By targeting top-division teams in less mainstream markets, Brera Holdings aims to strengthen its competitive position in regional tournaments, including those organized by the Union of European Football Associations (UEFA). These acquisitions are expected to enhance sponsorship revenues and create new growth opportunities.

Leveraging its expertise in capital raising and revenue generation, Brera Holdings also anticipates growing demand for its consulting services, providing advisory support to sports clubs, associations, investors, and others. Brera Holdings is headquartered in Dublin, Ireland, with additional offices in Milan, Italy.

Sporting Assets

Brera Holdings continues to grow its global sports portfolio with a series of strategic acquisitions and innovations, including the FENIX Trophy Tournament, a pan-European, non-professional football competition. Launched in September 2021 and organized by Brera FC, the tournament has been recognized by UEFA and described by BBC Sport as “the Champions League for amateurs.” In 2023, Brera FC hosted the tournament’s finals at Milan’s iconic San Siro Stadium.

In March 2023, Brera Holdings expanded into Africa by establishing Brera Tchumene FC in Mozambique. Starting in the country’s Second Division League, the team quickly earned promotion to Moçambola, Mozambique’s First Division League, by November 2023.

In April 2023, Brera Holdings further strengthened its European presence by acquiring a 90% stake in Fudbalski Klub Akademija Pandev, a first-division football team in North Macedonia. This acquisition provides access to two major UEFA competitions, solidifying the company’s position in European football.

Brera Holdings’ reach extends beyond football. In July 2023, it acquired majority ownership of UYBA Volley, an Italian Serie A1 women’s professional volleyball team, demonstrating its commitment to diversifying within top-tier sports.

In September 2023, Brera Holdings entered the Mongolian football market by acquiring Bayanzurkh Sporting Ilch FC, a Mongolian National Premier League team. For the 2024 season, the club was rebranded as Brera Ilch FC, further expanding Brera’s global footprint.

In January 2024, Brera Holdings initiated a proactive search for an Italian Serie B football club, aligning with its goal of bringing multi-club ownership opportunities to mass investors through its Nasdaq-listed shares.

In February 2024, the Brera Holdings Advisory Board was established with MLS founder and World Cup director Alan Rothenberg, luxury lifestyle executive Massimo Ferragamo, sports business leaders Paul Tosetti and Marshall Geller, and Italian football icon Giuseppe Rossi.

In June 2024, the North Macedonian women’s football club Tiverija Strumica officially became part of the Brera family with the establishment of a joint-stock company controlled by Brera Holdings called Women’s Football Club Tiverija Brera AD Strumica (“Brera Tiverija”). Brera Tiverija is now a wholly-owned subsidiary of Brera Strumica FC.

In September 2024 Brera announced that it signed an exclusive letter of intent to acquire an Italian Serie B club (the “LOI” and the “Club”). According to a CFA report published in June 2024, this expected strategic transaction, for an estimated purchase price of $21.6 million, would add first-year annual revenue of $10.8 million to Brera, and that revenue would likely increase by 25% each year for the next three years. The company’s capital valuation, projected the report, would also experience significant appreciation during this period.

In October 2024, Brera was recognized with the 2024 Social Impact Through Soccer Award at IMPACT 5050, an annual event honoring leaders and innovators who significantly impact their industries and communities. This is the second time Brera has won the award.

Market Opportunity

A report from IMARC Group, a global management consulting firm, reveals that the international football market generated approximately $3.3 billion in revenue in 2023, with projections to grow to $4.6 billion by 2032, reflecting a compound annual growth rate (CAGR) of 3.6%. Key drivers behind this growth include advancements in digitization, increasing sponsorship and partnership deals between brands and clubs, the rising interest in women’s professional soccer leagues, and the expansion of the e-sports and gaming sector.

In particular, Serie B Italian football clubs seem to present exceptionally attractive investment opportunities. As of September 2024, more than half of these clubs had appreciated between 80-100% in total market value, post-purchase.

As the world’s most-watched and most-played sport, soccer drives significant demand for football-related products and services, contributing to market growth. Broadcasting rights, sponsorships, and endorsement deals are also major revenue sources for clubs and organizations, with an expanding global fanbase generating new opportunities for financial growth, according to the report.

Management Team

With extensive experience in leadership and finance, Daniel McClory currently serves as the Executive Chairman and Director of Brera Holdings, PLC. He co-founded and held the position of Chief Executive Officer at Boustead & Company Limited, and previously served as the Managing Director, Head of Equity Capital Markets, and Head of China at Boustead Securities, LLC. Mr. McClory’s governance experience includes being a Board Director for USA Track & Field and a member of the Eastern Michigan University Champions Advisory Board. Mr. McClory’s expertise encompasses founding and financing equity capital markets, as well as navigating merger and acquisition transactions and initial public offerings. He holds a BS and MS from Eastern Michigan University, where he also received an honorary Doctor of Public Service. In addition to his professional qualifications, he is fluent in both English and Italian.

Pierre Galoppi serves as the CEO, Interim CFO, and director of Brera Holdings. With over 30 years of experience in strategic business and financial services, his career spans a variety of industries, including natural resources, aviation, cybersecurity, telecommunications, tourism, and international marketing. He has worked extensively across Latin America, the Caribbean, Canada, Europe, and the United States. Mr. Galoppi holds dual citizenship in Canada and Italy and is fluent in English, Spanish, Portuguese, Italian, and French. He earned a Bachelor of Commerce degree and an MBA from Concordia University in Montreal.

Maria Xing serves as the Head of Investments and Corporate Development. She is an executive who has specialized in MCO football (soccer) group investments for 777 Partners, where she was involved in sourcing, direct negotiations, due diligence, and closing deals, including acquiring a controlling stake in Brazilian Serie A football club, Vasco da Gama, and investing in Australian Premier League (“A-League”) side, Melbourne Victory FC. She also played a role in other professional sports franchise portfolio management, including topflight professional football clubs in Italy, France, Germany, and Belgium. Her background is in private equity, investment banking, and finance, with prior experience at The Raine Group, Credit Suisse, and EY (Ernst & Young), as well as previous sports industry experience at Liverpool Football Club in international business development. Ms. Xing earned an MBA from the Wharton School of the University of Pennsylvania and a B.S. from the New York University, Stern School of Business.

Additional Resources

Brera Holdings PLC (NASDAQ: BREA), closed Wednesday's trading session at $0.7008, up 0.0856898%, on 6,652 volume. The average volume for the last 3 months is 124,442 and the stock's 52-week low/high is $0.4999/$1.95.

Recent News

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF)

The QualityStocks Daily Newsletter would like to spotlightFathom Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF).

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) is a publicly traded Canadian minerals exploration company focused on exploring high-grade copper and gold deposits in North America. The company owns the Storm Copper Project and the Seal Zinc Deposit in Nunavut, Canada, and is currently exploring the Buckingham Gold Vein and critical metals prospects in central Virginia. Aston Bay is also in the advanced stages of negotiation on other properties with high-grade critical minerals potential in these areas.

The company believes in responsible exploration and carries out its work programs to the highest standards of social responsibility, environmental stewardship and health and safety. Aston Bay cares about leaving a net positive impact on the communities in which it works and engages with local representatives, Indigenous groups and government agencies to build respectful relationships through dialogue and collaborative processes. Depending on the stage of exploration, these efforts may include employment, contracting, training, community benefits and other agreements.

Aston Bay conducts exploration through safe, socially and environmentally responsible and sustainable work practices. The company embeds core values of health and safety throughout its operations by adhering to strict health and safety standards and practices that meet and/or exceed industry standards and government codes and regulations.

The company is headquartered in Toronto.

Projects

Storm Copper

The high-grade Storm Copper Deposit is located 112 kilometers south of the community of Resolute Bay, Nunavut, on western Somerset Island, just south of the past-producing Polaris Pb-Zn Mine. The property comprises 173 contiguous mining claims, including the Storm Copper and Seal Zinc projects, covering an area of approximately 541,795 acres.

The property has good access to established shipping lanes, and the landscape provides favorable conditions for development of roads and a protected deep-water port. Exploration is supported through excellent infrastructure in the nearby hamlet of Resolute Bay.

Aston Bay is partnered with American West Metals (ASX: AW1) at Storm. American West is responsible for all exploration expenditures, having aggressively advanced the project toward production and earned an 80% interest. This affords excellent optionality to the company’s shareholders, as Aston Bay is free carried with no required expenditures until the completion of a bankable feasibility study.

American West recently completed an Australian JORC-compliant Maiden Resource Estimate for Storm; the North American 43-101 compliant resource estimate is expected in Q1 2024. American West is cashed up and plans a multimillion-dollar resource expansion and new discovery drilling program for the summer of 2024.

The Buckingham County Gold Project

The gold-bearing system at the Buckingham County Gold Project in Virginia lies within a belt hosting past producing mines, current gold mines and advanced gold explorations, stretching through Georgia, the Carolinas, Virginia, Nova Scotia and Newfoundland.

Buckingham hosts a “Kirkland Lake-style” high grade gold vein returning values consistently over one ounce gold per ton and is underexplored both at depth and along almost one mile of strike length. These types of veins have excellent ESG qualities, as they are typically mined using a small footprint underground method, with gold extracted using simple and environmentally friendly gravity methods.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

A report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Thomas Ullrich is CEO and Director of Aston Bay. He has over 30 years of experience in mineral exploration and geoscience. Before joining Aston Bay, he was Chief Geologist North America for Antofagasta Minerals plc, investigating copper potential through extensive property evaluations and management of drill programs in the United States, Mexico and Canada. Prior to that, he was Senior Geologist for Almaden Minerals.

Sofia Harquail handles Investor Relations and Corporate Development at Aston Bay. She has over 15 years of experience in the private and public sectors of the mining industry. Before joining Aston Bay, she worked as a consultant for the Prospectors and Developers Association of Canada and for exempt market dealer Red Cloud Financial Services Inc. Ms. Harquail holds an M.A. from the University of Uppsala in Sweden and received her CPIR designation from the CIRI/Ivey Investor Relations Program. She also sits on the board of the Young Mining Professionals Toronto and is CSC Certified.

Aston Bay has a talented Board of Directors bringing broad experience from across the industry, encompassing resource expansion, mine development, mergers and acquisitions, and mining finance.

Ms. Jessie Liu-Ernsting has over 15 years of experience in the mining industry, spanning capital projects engineering, debt capital markets, private equity and corporate strategy at several firms, including Hudbay Minerals and Resource Capital Funds. She is currently VP Investor Relations and Communications at G Mining Ventures Corp.

Mr. Jeffrey R. Wilson has over 25 years’ experience in the mining industry, having served as a director, officer and advisor of multiple public and private companies in the mineral exploration and mining investment industries. Mr. Wilson is currently President & CEO of Precipitate Gold Corp.

Mr. Gary O’Connor has over 40 years of diverse experience as a mineral exploration and development professional in the management of successful resource projects as well as the evaluation, technical due diligence, and supervision of large mineral exploration and development projects through-out the world. While with Freeport, Mr. O’Connor worked on the due diligence and discovery of a major gold fraud on the Busang gold “deposit” in Kalimantan by Bre-X.

Mr. Mark J. Pryor is a geologist with a 40-year track record of successfully advancing multiple precious metal, copper, coal, REE and Li projects from discovery through to exploitation. He is currently Executive Vice President of the Exploration Division at The Electrum Group.

Aston Bay Holdings Ltd. (OTCQB: ATBHF), closed Wednesday's trading session at $0.0369, even for the day, on 393,490 volume. The average volume for the last 3 months is 491,400 and the stock's 52-week low/high is $0.03095/$0.107.

Recent News

SolarBank Corp. (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN)

The QualityStocks Daily Newsletter would like to spotlight SolarBank Corp. (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN).

SolarBank Corporation (NASDAQ: SUUN) (CSE: SUNN) is a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the United States. The company is committed to advancing the transition to sustainable energy by offering end-to-end services that include project origination, financing structuring, engineering, procurement, construction, and long-term operations and maintenance. SolarBank focuses on delivering innovative energy solutions through solar photovoltaic systems, battery energy storage systems (BESS), and electric vehicle (EV) charging infrastructure.

With a vision to provide scalable and reliable clean energy solutions, SolarBank has established itself as a leader in the renewable energy market by cultivating partnerships with utilities, commercial and industrial entities, municipalities, and residential customers. Its vertically integrated business model allows for optimized efficiency, cost management, and returns across diverse markets in North America. This end-to-end approach ensures greater control over project quality, costs, and operational outcomes, strengthening its competitive position.

Driven by a mission to create a greener future, SolarBank manages a robust portfolio of projects, including more than 100 megawatts (MW) of developed capacity and a pipeline exceeding one gigawatt (GW). The company’s commitment to sustainability and innovation makes it a recognized player in the renewable energy sector.

SolarBank has offices in Toronto, Ontario and New York.

Projects

SolarBank boasts an impressive and diverse portfolio of renewable energy initiatives that underline its leadership in the clean energy space. In the U.S., the company has over 250 MW of solar projects under development, principally in New York, focusing on community solar farms and commercial and industrial installations. Notably, SolarBank is developing several community solar projects in upstate New York, which will deliver clean energy to local residents and small businesses. Community solar projects, which are a cornerstone of SolarBank’s portfolio, provide scalable solutions for renters, homeowners, and small businesses to access affordable renewable energy, driving localized energy independence and economic savings.

In Canada, SolarBank has been a significant participant in Ontario’s Feed-in-Tariff program, where it has secured contracts for close to 200 MW of capacity. Its current management includes 70 solar power projects, totaling 28.8 MW of operational solar assets. The company’s expertise extends to the development and ownership of battery energy storage systems and EV charging stations, further diversifying its portfolio.

The company’s vertically integrated approach spans the entire project lifecycle, from initial site acquisition and grid interconnection to long-term operation and maintenance services. This ensures seamless execution and high-quality outcomes, providing value to stakeholders and supporting the transition to a clean energy future.

Market Opportunity

SolarBank operates within a growing renewable energy market driven by global demand for sustainable power solutions. In North America, favorable policies such as the Inflation Reduction Act in the United States and Canada’s investments in green technologies provide a robust foundation for renewable energy adoption. Solar PV installations and battery energy storage systems are at the forefront of this expansion, addressing energy reliability and grid stability while reducing carbon emissions.

The North American solar PV market was valued at $25.02 billion in 2019 and is projected to reach $120.74 billion by 2027, growing at a compound annual growth rate (CAGR) of 21.7% from 2020 to 2027. Likewise, the global BESS market is expected to expand from $7.8 billion in 2024 to $25.6 billion by 2029, at a CAGR of 26.9%, as reported by MarketsandMarkets. These trends are driven by the increasing integration of renewable energy sources, the need for grid resilience, and declining technology costs.

SolarBank’s operations have it well-positioned to capitalize on these opportunities. With a development pipeline exceeding one gigawatt (GW), the company is focused on meeting growing demand in community and commercial solar sectors. Decentralized energy solutions, such as virtual net metering and behind-the-meter systems, further enhance SolarBank’s market potential by addressing the critical need for flexible, cost-effective, and sustainable energy infrastructure. By leveraging its vertically integrated model and diversified portfolio, SolarBank stands as a key player in driving the renewable energy transition.

Leadership Team

Dr. Richard Lu, MD, MSc., MHSc., MBA, serves as President and CEO of SolarBank, bringing over 25 years of global energy experience. His leadership has been instrumental in advancing the company’s strategic initiatives across North America, Europe, and Asia, with a focus on renewable energy development and operational excellence.

Sam Sun, MBA, is the Chief Financial Officer of SolarBank. A Chartered Professional Accountant with more than 15 years of expertise in corporate finance, Mr. Sun has overseen financial strategies and internal controls across the cleantech, manufacturing, and mining sectors in Canada, the U.S., and China.

Andrew van Doorn, PE, serves as Chief Operating Officer, with nearly three decades of experience in engineering and construction. Mr. van Doorn has successfully led projects totaling over 200 MW of solar capacity and is a former Chairman of the Canadian Solar Industries Association.

Tracy Zheng, MBA, Chief Development Officer, has over 25 years of experience in brand marketing, business development, and solar project operations. She has spearheaded sales initiatives, conducted feasibility studies, and negotiated key partnerships that drive SolarBank’s growth.

Matt Wayrynen, Executive Chairman and Director, has a background in resource company management, venture capital, and mergers and acquisitions. Under his leadership, Solar Flow-Through Funds, where Mr. Wayrynen acted as CEO, was acquired by SolarBank, enhancing its asset portfolio and growth prospects.


Forward Looking Statements

This report contains forward-looking statements and forward-looking information ‎within the meaning of Canadian securities legislation (collectively, “forward-looking ‎statements”) that relate to the Company’s current expectations and views of future events. ‎Any statements that express, or involve discussions as to, expectations, beliefs, plans, ‎objectives, assumptions or future events or performance (often, but not always, through the ‎use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will ‎continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, ‎‎”projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be ‎forward-looking statements and may involve estimates, assumptions and uncertainties ‎which could cause actual results or outcomes to differ materially from those expressed in ‎such forward-looking statements. In particular and without limitation, this report ‎contains forward-looking statements pertaining to the Company’s expectations regarding its industry trends and overall market growth of the data center market; the Company’s expansion into the data center market, including its pursuit of opportunities as a developer, owner, and strategic partner in data center infrastructure; supporting the demand for high-performance, sustainable energy solutions within the sector; details of the company’s business plan including development of solar power projects, battery storage projects and EV charging projects; the completion of any contracts for, or construction of, any data center, solar power, battery storage or EV projects; the receipt of interconnection approval, permits and financing to be able to construct projects; the receipt of incentives for projects; and the size of the Company’s development pipeline. No assurance ‎can be given that these expectations will prove to be correct and such forward-looking ‎statements included in this report should not be unduly relied upon. These ‎statements speak only as of the date of this report.‎

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. In making the forward looking statements included in this report, the Company has made various material assumptions, including but not limited to: obtaining the necessary regulatory approvals; that regulatory requirements will be maintained; general business and economic conditions; the Company’s ability to successfully execute its plans and intentions; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and services offered by the Company’s competitors; that the Company’s current good relationships with its service providers and other third parties will be maintained; and government subsidies and funding for renewable energy will continue as currently contemplated. Although the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and the Company cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements.

Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Forward-‎Looking Statements” and “Risk ‎Factors” in the Company’s most recently completed Annual Information Form, and other public filings of the Company, which include: the Company may be adversely affected by volatile solar power market and industry conditions; the execution of the Company’s growth strategy depends upon the continued availability of third-party financing arrangements; the Company’s future success depends partly on its ability to expand the pipeline of its energy business in several key markets; governments may revise, reduce or eliminate incentives and policy support schemes for solar and battery storage power; general global economic conditions may have an adverse impact on our operating performance and results of operations; the Company’s project development and construction activities may not be successful; developing and operating solar projects exposes the Company to various risks; the Company faces a number of risks involving Power Purchase Agreements (“PPAs”) and project-level financing arrangements; any changes to the laws, regulations and policies that the Company is subject to may present technical, regulatory and economic barriers to the purchase and use of solar power; the markets in which the Company competes are highly competitive and evolving quickly; an anti-circumvention investigation could adversely affect the Company by potentially raising the prices of key supplies for the construction of solar power projects; foreign exchange rate fluctuations; a change in the Company’s effective tax rate can have a significant adverse impact on its business; seasonal variations in demand linked to construction cycles and weather conditions may influence the Company’s results of operations; the Company may be unable to generate sufficient cash flows or have access to external financing; the Company may incur substantial additional indebtedness in the future; the Company is subject to risks from supply chain issues; risks related to inflation; unexpected warranty expenses that may not be adequately covered by the Company’s insurance policies; if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the renewable energy market; there are a limited number of purchasers of utility-scale quantities of electricity; compliance with environmental laws and regulations can be expensive; corporate responsibility may adversely impose additional costs; the future impact of any resurgence of COVID-19 on the Company is unknown at this time; the Company has limited insurance coverage; the Company will be reliant on information technology systems and may be subject to damaging cyberattacks; the Company may become subject to litigation; there is no guarantee on how the Company will use its available funds; the Company will continue to sell securities for cash to fund operations, capital expansion, mergers and acquisitions that will dilute the current shareholders; and future dilution as a result of financings.

The Company undertakes no obligation to update or revise any ‎forward-looking statements, whether as a result of new information, future events or ‎otherwise, except as may be required by law. New factors emerge from time to time, and it ‎is not possible for the Company to predict all of them, or assess the impact of each such ‎factor or the extent to which any factor, or combination of factors, may cause results to ‎differ materially from those contained in any forward-looking statement. Any forward-‎looking statements contained in this report are expressly qualified in their entirety by ‎this cautionary statement.‎

SolarBank Corp. (NASDAQ: SUUN), closed Wednesday's trading session at $2.1, off by 4.1096%, on 9,733 volume. The average volume for the last 3 months is 182,957 and the stock's 52-week low/high is $1.95/$6.87.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.